Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE

Strs Ohio cut its position in Maze Therapeutics, Inc. (NASDAQ:MAZE) by 61.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,900 shares of the company’s stock after selling 29,000 shares during the period. Strs Ohio’s holdings in Maze Therapeutics were worth $464,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the company. Ensign Peak Advisors Inc purchased a new stake in Maze Therapeutics during the 2nd quarter worth about $227,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Maze Therapeutics by 10.6% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after acquiring an additional 438,274 shares during the last quarter. Virtus Investment Advisers LLC acquired a new stake in shares of Maze Therapeutics during the 2nd quarter worth about $85,000. CW Advisors LLC purchased a new stake in Maze Therapeutics during the second quarter worth approximately $371,000. Finally, CWM LLC purchased a new stake in Maze Therapeutics during the second quarter worth approximately $28,000.

Analyst Ratings Changes

Several equities analysts have commented on MAZE shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Wells Fargo & Company began coverage on shares of Maze Therapeutics in a research report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 target price on the stock. Wedbush lifted their price target on shares of Maze Therapeutics from $35.00 to $36.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Guggenheim reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Friday, December 19th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Maze Therapeutics in a report on Wednesday. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $44.50.

Maze Therapeutics Price Performance

Shares of Maze Therapeutics stock opened at $43.58 on Friday. The firm’s fifty day simple moving average is $40.85 and its 200-day simple moving average is $29.07. Maze Therapeutics, Inc. has a 12 month low of $6.71 and a 12 month high of $47.36. The stock has a market capitalization of $2.10 billion and a price-to-earnings ratio of -2.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Insider Activity at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.58, for a total value of $405,800.00. Following the transaction, the senior vice president owned 12,965 shares of the company’s stock, valued at approximately $526,119.70. The trade was a 43.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Atul Dandekar sold 72,400 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the sale, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. This trade represents a 87.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 172,500 shares of company stock worth $7,002,267 in the last quarter.

Maze Therapeutics Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.